Key Takeaways
- The capex story finally goes live: Revenue grew 22.1% YoY in Q1, but the real inflection is that expanded fermentation capacity starts full-scale production by end of August 2026, with output contributing from Q2 and fully in H2.
- Two acquisitions reshape the company: GTBL announced the MicroBiopharm Japan acquisition (precision fermentation, peptides, plasmids, ADCs, enzyme engineering) and 13 Sanofi anti-TB/anti-infective brands across 55 countries, transforming it from a sold-out intermediate maker into a fermentation-based CDMO with forward integration.
- Margins already expanded sharply: EBITDA margin rose 867 bps YoY to 47.5%, with EBITDA up 49.4% YoY to ₹20.8 crores, before any contribution from the new capacity or acquisitions.
- The flat years had a simple cause: GTBL has been sold out for 4–5 years, so revenue could not grow; management spent that time building infrastructure and admits projects ran about a year late.
- What to watch next quarter: Whether expanded capacity actually ramps on schedule, the MicroBiopharm Japan closing terms and funding mix, and any early synergy signals from the Sanofi portfolio integration.
The Capacity Inflection
- Why growth stalled: GTBL has been sold out in capacity for 4–5 years, so revenue and margins were flat because there was nothing more to sell. Fermentation capacity is not easy to expand, and the first few years went to upgrading old facilities, the next three to creating new infrastructure.
- What changed: The company has practically doubled fermentation capacity, though not all expansion is for Rifampicin; some went to R&D and cGMP pilot facilities.
- The API block delay: API block commercialization was delayed approximately 2 years because GTBL lacked sufficient fermentation capacity. All intermediate production was already contracted to long-term customers, so API production could not begin without cannibalizing existing supplies.
- Binary utilization: Fermentation capacity runs at 0 or 100, so the expanded capacity will run at full scale from day one. The manufacturing site starts full steam by end of August 2026.
- Revenue timing: Output from expanded capacity should start appearing to a certain extent from Q2 FY27, with full contribution in the second half of the year; both API and fermentation blocks will be up and running.
- Asset turns: Management expects around 1.4x–1.5x asset turns on the ~₹200 crores of new fermentation and API facility capex.
- Customer target: The target is everyone using the intermediate in and outside the country.
Sachin Patel: "We have been in a mode whereby our business has been pretty, I would say, flat, but at the same time, we've been sold out in capacity, and we have been in a working phase whereby we've been investing in capex and building the infrastructure that we have. And admittedly, we have been late by almost about a year in terms of the projects that have been implemented, but now it's all ready to go."
The MicroBiopharm Japan Acquisition
- What GTBL is buying: MicroBiopharm Japan specializes in precision fermentation and other technologies, adding therapy areas across immunosuppressants, oncology and anti-infectives, plus technical capabilities in peptides, plasmids, ADCs and enzyme engineering.
- Commercialization status: At MBJ, all technology areas except ADCs are already commercialized, meaning at least one project developed and commercialized with respective GMP accreditations. ADCs is a relatively new patented technology with no CDMO project bagged yet.
- The jump-start logic: Management says MBJ gives GTBL a 7–8 year head start because capabilities, projects, supplies and relationships with big pharma in Japan and globally are already in place.
- Under PE ownership: Top line may not have improved over the last 5 years, but significant bottom-line improvement occurred through value-added businesses and technologies that improved EBITDA significantly; cash flows and cash flow situation are strong.
- Deal origin: GTBL approached MicroBiopharm 2.5 years ago to ask if they were ready for sale; the PE fund's life closing drove the sale.
- Funding: Funding for the deal is "pretty much" secured, with some last-minute approvals required; multiple funding avenues are being prepared to achieve optimal debt-equity mix by month-end closing.
- Interest cost: Management expects interest cost in the two acquisition geographies to be significantly lower than the 10% mentioned by an analyst; does not see interest outflow at that level; expects the business to be cash flow positive from the very beginning.
- Enzyme technology: Management has clear ideas on commercializing MBJ's enzyme technology (including P450 enzyme library) within GTBL; expects to do a fair amount of work within the first year and bring quick wins in synergy between the two companies.
- ADC caution: ADCs at MBJ have the technology but no project bagged from a CDMO perspective yet; it is an innovative technology and only time will tell how much interest it gains from prospective customers.
Sachin Patel: "Now with MicroBiopharm, it gives us a jump start of 7 to 8 years because all these capabilities are there, projects are there, supplies are there and of course, relationships with big pharma in Japan and a few big pharma globally also."
The Sanofi Brand Acquisition
- What GTBL is buying: 13 selected global brands from Sanofi France in anti-TB and anti-infective segments, providing access to 55 countries across Europe, Middle East and Africa.
- Strategic logic: The portfolio secures GTBL's bread and butter, the intermediate business it currently runs, while adding forward integration of some APIs that gives a healthy margin stack.
- Margin opportunity: Management expects significant improvement in margins by integrating GTBL's own API into the supply chain versus the API Sanofi currently uses; distribution improvement is also an opportunity.
- API integration timeline: Eventually planning to use API manufactured from the Indian facility for Sanofi products; expecting approvals for GTBL APIs in coming years, will be ready much before Sanofi portfolio integration happens.
- Manufacturing transition: Post-closing, a 3-year transition service agreement with Sanofi covers step-by-step transfer, starting with country-by-country transfer of marketing authorizations, culminating in all manufacturing moving into GTBL's control using CMOs (some already used by Sanofi, some to be created); management hopes to complete much earlier than 3 years, with all tech transfers expected complete in the first year.
- Themis relationship: Sanofi business will be contracted to CMOs, which may or may not be Themis; as plans stand, it will not be Themis because of existing projects at Themis; production will move from Sanofi to other sites on a CMO basis, which may or may not be inside India.
- Marketing: In certain markets where Sanofi was not doing enough, GTBL has already tied up with strong distributors to take these products to market. Intend to go ahead with Sanofi distributors where strong; more aggressive marketing is something management is excited about.
- Branding: Brand names will remain as they are; manufacturer will change from Sanofi to Themis Biosyn.
- Closing timeline: The Sanofi acquisition is expected to take about 6 to 9 months or longer, with long stop date of June next year, due to regulatory approvals required from over 50 countries.
Sachin Patel: "It essentially secures our bread and butter, which is what we are making right now."
Strategy: Fermentation-Based CDMO
- The merger withdrawal: The planned merger with Themis Medicare (announced around November 2024) was withdrawn after approximately 6 months. GTBL appointed an external firm for strategic options, which clarified the fermentation-based CDMO direction, and management decided the merger would dilute GTBL's focus.
- Acquisition philosophy: Management is not getting into any geography or business where it takes responsibility for turning the business around; it is bringing synergies in both places so that 1 plus 1 is equal to significantly more than 2.
- Rifamycin-S economics: Management views the market shift from Rifampicin toward Rifapentine favorably because manufacturing 1 kilo of Rifapentine requires more Rifa-S than manufacturing Rifampicin; company is ready with both APIs.
- Customer concentration: Endeavor is to get into the supply chain and sell intermediate to anyone in the country and outside who is manufacturing these APIs.
- Optimus Drugs dispute: Over the last 6–9 months GTBL did not supply to Optimus and still easily sold out capacity; there are more than enough buyers for the same product in the country. The dispute is behind them; both companies worked constructively to resolve it and are restarting business.
- Post-acquisition margins: Once integration is completed and stabilization done, management hopes to be close to current GTBL margins.
Sachin Patel: "We felt that if we would be doing anything else, we will be diluting what GTBL is doing. And hence, from a perspective of GTBL, it was decided that we want to grow this particular business as a fermentation-based CDMO and not get into other businesses, which were predominantly domestic in nature."
Financial Position & Capital Structure
- Equity raise: Currently decided to raise equity up to ₹1,000 crores; debt amount not yet finalized, keeping options open for optimal mix.
- Base-business capex: Around ₹20-odd crores total for FY27 including maintenance capex; most capex already done.
- Promoter pledge reduction: Expected to go down significantly within a year to 15 months.
- Hybrid power plant: Phase 1 expected live in September, Phase 2 two months later; should improve EBITDA margins by allowing power at significantly lower price.
- Conference call resumption: Management committed to holding calls on a quarterly or at minimum semi-annual basis going forward.
- Unanswered on encumbrance: An analyst asked about promoter encumbrance, noting around 2% of encumbrance was released in July and asking about the action plan for further reduction; management said "Sorry, I'm not aware about this particular detail" and did not answer.
- Unanswered on MBJ revenue split: An analyst asked what revenue is currently being generated from each of MBJ's technology verticals (precision fermentation, ADCs, enzymes, etc.); management declined to divulge, stating "we are not in a position to diverge at this stage."
Sachin Patel: "We are not getting into any geography or any business where we are taking the responsibility of turning the business around. We are simply bringing in the synergies in both the places, which can add value, whereby 1 plus 1 is equal to more -- significantly more than 2."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Expanded capacity production | Manufacturing site starts full steam; fermentation capacity fully operational and running at full scale | End of August 2026 |
| Revenue from expanded capacity | Partial contribution from Q2 FY27; full contribution in H2 | Q2 FY27 / H2 FY27 |
| MicroBiopharm Japan closing | Deal closes with funding secured and optimal debt-equity mix | Month-end closing |
| Sanofi acquisition closing | Regulatory approvals from 50+ countries; long stop date June next year | 6–9 months or longer |
| Sanofi manufacturing transition | 3-year TSA; all tech transfers expected complete in first year | First year post-closing |
| Hybrid power plant | Phase 1 live September, Phase 2 two months later; improves EBITDA margins | September / November 2026 |
| Promoter pledge reduction | Expected to go down significantly | Within a year to 15 months |
| Base-case growth | High-teen growth on base-case basis | No specific timeline given |
| Post-acquisition margins | Close to current GTBL margins after integration and stabilization | No specific timeline given |
| MBJ enzyme commercialization | Fair amount of work and quick wins in synergy | Within first year |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹43.8 crores, up 22.1% YoY from ₹35.9 crores |
| EBITDA | ₹20.8 crores, up 49.4% YoY |
| EBITDA margin | 47.5%, up 867 bps YoY |
| Profit after tax | ₹11.1 crores, up 22.1% YoY from ₹9.1 crores |
| Base-case growth expectation | High-teen basis |
| Gross block | ₹435 crores in FY26 including CWIP, up from ₹62 crores in FY23 |
| Incremental gross block added over last 3 years | ₹370 crores |
| Asset turn expectation on new fermentation and API facilities | 1.4x to 1.5x on ₹200 crores |
| Remaining base-business capex | ₹10–15 crores for last-mile work; total FY27 capex including maintenance around ₹20-odd crores |
| Fermentation capacity expansion | 540 KL additional capacity, fully operational by end of August |
| Hybrid power plant Phase 1 | Expected live in September, second phase 2 months later |
| Promoter pledge | 48–48.5% as of June, with 1.5–2% released in July; expected to decline significantly within 12–15 months |
| Sanofi portfolio | 13 brands across anti-TB and anti-infective segments, access to 55 countries across Europe, Middle East and Africa |
| Sanofi transition service agreement | 3 years |
| MicroBiopharm CDMO share of business | 60% |
| MicroBiopharm revenue split | 60% Japan, 40% outside Japan |
| MicroBiopharm formulation share | 4–5%, predominantly fermentation-based APIs |
| Equity raise planned | Up to ₹1,000 crores |